Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function.

Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B, Chakarov S, See P, Low D, Low G, Garcia-Miralles M, Zeng R, Zhang J, Goh CC, Gul A, Hubert S, Lee B, Chen J, Low I, Shadan NB, Lum J, Wei TS, Mok E, Kawanishi S, Kitamura Y, Larbi A, Poidinger M, Renia L, Ng LG, Wolf Y, Jung S, Önder T, Newell E, Huber T, Ashihara E, Garel S, Pouladi MA, Ginhoux F.

Immunity. 2020 Feb 18;52(2):417-418. doi: 10.1016/j.immuni.2020.01.004. No abstract available.

PMID:
32075730
2.

Loss-of-function mutations in UDP-Glucose 6-Dehydrogenase cause recessive developmental epileptic encephalopathy.

Hengel H, Bosso-Lefèvre C, Grady G, Szenker-Ravi E, Li H, Pierce S, Lebigot É, Tan TT, Eio MY, Narayanan G, Utami KH, Yau M, Handal N, Deigendesch W, Keimer R, Marzouqa HM, Gunay-Aygun M, Muriello MJ, Verhelst H, Weckhuysen S, Mahida S, Naidu S, Thomas TG, Lim JY, Tan ES, Haye D, Willemsen MAAP, Oegema R, Mitchell WG, Pierson TM, Andrews MV, Willing MC, Rodan LH, Barakat TS, van Slegtenhorst M, Gavrilova RH, Martinelli D, Gilboa T, Tamim AM, Hashem MO, AlSayed MD, Abdulrahim MM, Al-Owain M, Awaji A, Mahmoud AAH, Faqeih EA, Asmari AA, Algain SM, Jad LA, Aldhalaan HM, Helbig I, Koolen DA, Riess A, Kraegeloh-Mann I, Bauer P, Gulsuner S, Stamberger H, Ng AYJ, Tang S, Tohari S, Keren B, Schultz-Rogers LE, Klee EW, Barresi S, Tartaglia M, Mor-Shaked H, Maddirevula S, Begtrup A, Telegrafi A, Pfundt R, Schüle R, Ciruna B, Bonnard C, Pouladi MA, Stewart JC, Claridge-Chang A, Lefeber DJ, Alkuraya FS, Mathuru AS, Venkatesh B, Barycki JJ, Simpson MA, Jamuar SS, Schöls L, Reversade B.

Nat Commun. 2020 Jan 30;11(1):595. doi: 10.1038/s41467-020-14360-7.

3.

Reprint of: Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease.

Radulescu CI, Garcia-Miralles M, Sidik H, Bardile CF, Yusof NABM, Lee HU, Ho EXP, Chu CW, Layton E, Low D, De Sessions PF, Pettersson S, Ginhoux F, Pouladi MA.

Neurobiol Dis. 2020 Feb;135:104744. doi: 10.1016/j.nbd.2020.104744. Epub 2020 Jan 10.

4.

Huntingtin confers fitness but is not embryonically essential in zebrafish development.

Sidik H, Ang CJ, Pouladi MA.

Dev Biol. 2020 Feb 1;458(1):98-105. doi: 10.1016/j.ydbio.2019.10.037. Epub 2019 Nov 2.

PMID:
31682806
5.

Generation of four H1 hESC sublines carrying a hemizygous knock-out/mutant MECP2.

Zeng R, Sidik H, Robinson KS, Zhong FL, Reversade B, Pouladi MA.

Stem Cell Res. 2019 Oct;40:101533. doi: 10.1016/j.scr.2019.101533. Epub 2019 Aug 9.

6.

Novel mutation in HTRA1 in a family with diffuse white matter lesions and inflammatory features.

Ziaei A, Xu X, Dehghani L, Bonnard C, Zellner A, Jin Ng AY, Tohari S, Venkatesh B, Haffner C, Reversade B, Shaygannejad V, Pouladi MA.

Neurol Genet. 2019 Jul 8;5(4):e345. doi: 10.1212/NXG.0000000000000345. eCollection 2019 Aug.

7.

Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.

Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, Hayden MR, Pouladi MA.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622-9627. doi: 10.1073/pnas.1818042116. Epub 2019 Apr 23.

8.

Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS.

van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, Drögemöller BI, Pouladi MA, Leen R, Brand-Arzamendi K, Dobritzsch D, Dolzhenko E, Eberle MA, Hayward B, Jones MJ, Karbassi F, Kobor MS, Koster J, Kumari D, Li M, MacIsaac J, McDonald C, Meijer J, Nguyen C, Rajan-Babu IS, Scherer SW, Sim B, Trost B, Tseng LA, Turkenburg M, van Vugt JJFA, Veldink JH, Walia JS, Wang Y, van Weeghel M, Wright GEB, Xu X, Yuen RKC, Zhang J, Ross CJ, Wasserman WW, Geraghty MT, Santra S, Wanders RJA, Wen XY, Waterham HR, Usdin K, van Karnebeek CDM.

N Engl J Med. 2019 Apr 11;380(15):1433-1441. doi: 10.1056/NEJMoa1806627.

PMID:
30970188
9.

Impaired Remyelination in a Mouse Model of Huntington Disease.

Teo RTY, Ferrari Bardile C, Tay YL, Yusof NABM, Kreidy CA, Tan LJ, Pouladi MA.

Mol Neurobiol. 2019 Oct;56(10):6873-6882. doi: 10.1007/s12035-019-1579-1. Epub 2019 Apr 2.

PMID:
30937636
10.

Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects.

Ooi J, Langley SR, Xu X, Utami KH, Sim B, Huang Y, Harmston NP, Tay YL, Ziaei A, Zeng R, Low D, Aminkeng F, Sobota RM, Ginhoux F, Petretto E, Pouladi MA.

Cell Rep. 2019 Feb 26;26(9):2494-2508.e7. doi: 10.1016/j.celrep.2019.02.008.

11.

Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease.

Radulescu CI, Garcia-Miralles M, Sidik H, Bardile CF, Yusof NABM, Lee HU, Ho EXP, Chu CW, Layton E, Low D, De Sessions PF, Pettersson S, Ginhoux F, Pouladi MA.

Neurobiol Dis. 2019 Jul;127:65-75. doi: 10.1016/j.nbd.2019.02.011. Epub 2019 Feb 23.

12.

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.

Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA.

Mol Neurobiol. 2019 Jun;56(6):4464-4478. doi: 10.1007/s12035-018-1393-1. Epub 2018 Oct 17.

PMID:
30334188
13.

Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model.

Chang WT, Puspitasari F, Garcia-Miralles M, Yeow LY, Tay HC, Koh KB, Tan LJ, Pouladi MA, Chuang KH.

NMR Biomed. 2018 Dec;31(12):e4007. doi: 10.1002/nbm.4007. Epub 2018 Sep 27.

PMID:
30260561
14.

A homozygous loss-of-function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability.

Chia PH, Zhong FL, Niwa S, Bonnard C, Utami KH, Zeng R, Lee H, Eskin A, Nelson SF, Xie WH, Al-Tawalbeh S, El-Khateeb M, Shboul M, Pouladi MA, Al-Raqad M, Reversade B.

Elife. 2018 May 22;7. pii: e32451. doi: 10.7554/eLife.32451.

15.

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.

JCI Insight. 2017 Dec 7;2(23). pii: 95665. doi: 10.1172/jci.insight.95665.

16.

A thiol probe for measuring unfolded protein load and proteostasis in cells.

Chen MZ, Moily NS, Bridgford JL, Wood RJ, Radwan M, Smith TA, Song Z, Tang BZ, Tilley L, Xu X, Reid GE, Pouladi MA, Hong Y, Hatters DM.

Nat Commun. 2017 Sep 7;8(1):474. doi: 10.1038/s41467-017-00203-5.

17.

Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function.

Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B, Chakarov S, See P, Low D, Low G, Garcia-Miralles M, Zeng R, Zhang J, Goh CC, Gul A, Hubert S, Lee B, Chen J, Low I, Shadan NB, Lum J, Wei TS, Mok E, Kawanishi S, Kitamura Y, Larbi A, Poidinger M, Renia L, Ng LG, Wolf Y, Jung S, Önder T, Newell E, Huber T, Ashihara E, Garel S, Pouladi MA, Ginhoux F.

Immunity. 2017 Jul 18;47(1):183-198.e6. doi: 10.1016/j.immuni.2017.06.017. Erratum in: Immunity. 2020 Feb 18;52(2):417-418.

18.

Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.

Xu X, Tay Y, Sim B, Yoon SI, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C, Low D, Ng AYJ, Loh M, Venkatesh B, Ginhoux F, Augustine GJ, Pouladi MA.

Stem Cell Reports. 2017 Mar 14;8(3):619-633. doi: 10.1016/j.stemcr.2017.01.022. Epub 2017 Feb 23.

19.

Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle.

Julien SG, Kim SY, Brunmeir R, Sinnakannu JR, Ge X, Li H, Ma W, Yaligar J, Kn BP, Velan SS, Röder PV, Zhang Q, Sim CK, Wu J, Garcia-Miralles M, Pouladi MA, Xie W, McFarlane C, Han W, Xu F.

PLoS Biol. 2017 Feb 16;15(2):e1002597. doi: 10.1371/journal.pbio.1002597. eCollection 2017 Feb.

20.

A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.

Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, Slama R, Ooi J, Pouladi MA, Yang XW, Swayze EE, Seth PP, Hayden MR.

Hum Mol Genet. 2017 Mar 15;26(6):1115-1132. doi: 10.1093/hmg/ddx021.

PMID:
28104789
21.

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.

Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652.

22.

Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells.

Itahana Y, Zhang J, Göke J, Vardy LA, Han R, Iwamoto K, Cukuroglu E, Robson P, Pouladi MA, Colman A, Itahana K.

Sci Rep. 2016 Jun 27;6:28112. doi: 10.1038/srep28112.

23.

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.

Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR.

Sci Rep. 2016 May 4;6:25333. doi: 10.1038/srep25333.

24.

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease.

Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, Pouladi MA.

Hum Mol Genet. 2016 Jul 1;25(13):2621-2632. Epub 2016 Apr 28.

25.

Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD.

Riechers SP, Butland S, Deng Y, Skotte N, Ehrnhoefer DE, Russ J, Laine J, Laroche M, Pouladi MA, Wanker EE, Hayden MR, Graham RK.

Hum Mol Genet. 2016 Apr 15;25(8):1600-18. doi: 10.1093/hmg/ddw036. Epub 2016 Feb 11.

PMID:
26908611
26.

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

Garcia-Miralles M, Ooi J, Ferrari Bardile C, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA.

Exp Neurol. 2016 Apr;278:4-10. doi: 10.1016/j.expneurol.2016.01.019. Epub 2016 Jan 26.

27.

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR.

Neurobiol Dis. 2015 Apr;76:46-56. doi: 10.1016/j.nbd.2015.01.002. Epub 2015 Feb 3.

28.

Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice.

Wong BKY, Ehrnhoefer DE, Graham RK, Martin DDO, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR.

Neurobiol Dis. 2015 Apr;76:24-36. doi: 10.1016/j.nbd.2014.12.030. Epub 2015 Jan 9.

PMID:
25583186
29.

Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.

Ooi J, Hayden MR, Pouladi MA.

Mol Neurobiol. 2015 Dec;52(3):1850-1861. doi: 10.1007/s12035-014-8974-4. Epub 2014 Nov 15.

30.

Preclinical models: needed in translation? A Pro/Con debate.

Philips T, Rothstein JD, Pouladi MA.

Mov Disord. 2014 Sep 15;29(11):1391-6. doi: 10.1002/mds.26010. Review.

PMID:
25216370
31.

Choosing an animal model for the study of Huntington's disease.

Pouladi MA, Morton AJ, Hayden MR.

Nat Rev Neurosci. 2013 Oct;14(10):708-21. doi: 10.1038/nrn3570. Review.

PMID:
24052178
32.

Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.

Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I.

Nat Med. 2013 Aug;19(8):1030-8. doi: 10.1038/nm.3246. Epub 2013 Jul 14.

33.

A fully humanized transgenic mouse model of Huntington disease.

Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR.

Hum Mol Genet. 2013 Jan 1;22(1):18-34. doi: 10.1093/hmg/dds397. Epub 2012 Sep 21.

34.

Heritability of pain sensitivity and opioid analgesia.

Huang YH, Pouladi MA.

Clin Genet. 2012 Oct;82(4):376-7. doi: 10.1111/j.1399-0004.2012.01946.x. Epub 2012 Aug 30. No abstract available.

PMID:
22880893
35.

PS: pain and sodium channels.

Teo RT, Pouladi MA.

Clin Genet. 2012 Oct;82(4):374-6. doi: 10.1111/j.1399-0004.2012.01945.x. Epub 2012 Aug 30. No abstract available.

PMID:
22880841
36.

Painful gains: missense mutations in SCN9A and idiopathic small nerve fibre neuropathy.

Pouladi MA.

Clin Genet. 2012 Oct;82(4):374. doi: 10.1111/j.1399-0004.2012.01944.x. Epub 2012 Aug 30. No abstract available.

PMID:
22880747
37.

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.

Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR.

Neurobiol Dis. 2012 Dec;48(3):282-9. doi: 10.1016/j.nbd.2012.06.026. Epub 2012 Jul 10.

PMID:
22796360
38.

Polyglutamine diseases and the risk of cancer.

Pouladi MA, Hayden MR.

Lancet Oncol. 2012 Jun;13(6):569-71. doi: 10.1016/S1470-2045(12)70167-5. No abstract available.

PMID:
22652230
39.

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.

Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR.

Hum Mol Genet. 2012 May 15;21(10):2219-32. doi: 10.1093/hmg/dds037. Epub 2012 Feb 9.

PMID:
22328089
40.

Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice.

Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, Ehrnhoefer DE, Vaid K, Miller FD, Deshmukh M, Howland D, Hayden MR.

Hum Mol Genet. 2012 May 1;21(9):1954-67. doi: 10.1093/hmg/dds005. Epub 2012 Jan 18.

41.

Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.

Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR.

J Huntingtons Dis. 2012;1(2):243-60. doi: 10.3233/JHD-120038.

PMID:
25063333
42.

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation.

Pouladi M.

Clin Genet. 2011 Jun;79(6):508-10. doi: 10.1111/j.1399-0004.2011.01663.x. Epub 2011 Apr 20. No abstract available.

PMID:
21388370
43.

Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.

Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, Perkins G, Bossy-Wetzel E.

Nat Med. 2011 Mar;17(3):377-82. doi: 10.1038/nm.2313. Epub 2011 Feb 20.

44.

Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.

Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR.

J Neurosci. 2010 Nov 10;30(45):15019-29. doi: 10.1523/JNEUROSCI.2071-10.2010.

45.

Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease.

Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR.

Neurobiol Dis. 2011 Feb;41(2):249-60. doi: 10.1016/j.nbd.2010.09.012. Epub 2010 Sep 25.

PMID:
20875859
46.

Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes.

Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E.

J Neurosci. 2010 Aug 11;30(32):10844-50. doi: 10.1523/JNEUROSCI.0917-10.2010.

47.

Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.

Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA.

Neuron. 2010 Jan 28;65(2):178-90. doi: 10.1016/j.neuron.2010.01.008.

48.

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR.

Hum Mol Genet. 2010 Apr 15;19(8):1528-38. doi: 10.1093/hmg/ddq026. Epub 2010 Jan 22.

49.

Taking a SUMO off a TRP for bad conduct.

Pouladi MA.

Clin Genet. 2010 Apr;77(4):328-30. doi: 10.1111/j.1399-0004.2009.01366_2.x. Epub 2010 Jan 20. No abstract available.

PMID:
20095982
50.

Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR.

Hum Mol Genet. 2010 Apr 15;19(8):1438-52. doi: 10.1093/hmg/ddq018. Epub 2010 Jan 20.

Supplemental Content

Loading ...
Support Center